Supplement
NMN
Longevity · Nicotinamide mononucleotide
NMN is a precursor of the cellular molecule NAD+ and is considered a core longevity supplement. NAD levels in the blood rise measurably – this has not translated into a clinical benefit, and there is a safety signal for one of its breakdown products.
What NMN is
Nicotinamide mononucleotide is a precursor of NAD+, a molecule involved in energy production and DNA repair. NAD+ levels decline with age; this is where the idea of raising them again via a precursor comes from.
The pathway is biochemically plausible and therefore popular; hardly any longevity product is more overhyped.
Why the NAD increase says little
That NMN raises NAD levels in the blood has been shown. This measurement, however, is a surrogate marker, that is, a lab value that is merely meant to reflect a course. Whether wellbeing, performance or disease rates change along with it is a separate question.
This is exactly where the chain breaks: in the study that showed the NAD increase, the main question failed at the same time. The increase in tissue, which is what would matter, is also poorly supported.
What has been tested in humans
A systematic search of Europe PMC and ClinicalTrials.gov found no randomized trial with a hard endpoint – that is, with mortality, cardiovascular events, bone fractures or dementia. The largest registered NMN studies, with 200 and 138 participants, are still ongoing.
What exists are short studies with lab values and functional tests, plus two meta-analyses that find nothing.
What is well supported
- The substance measurably reaches the metabolism. In the double-blind study by Morifuji 2024 (n=60, 250 mg per day, 12 weeks, older adults), NAD+ in the blood and the metabolites 2PY and 4PY rose significantly. This shows that intake actually raises the NAD pathway – absorption is no longer an open question.
- Safety has been assessed by regulators. In 2026, the EFSA Panel on Nutrition and Food Allergens classified beta-NMN as a novel food as safe for adults up to 300 mg per day, excluding pregnant and breastfeeding women; the safety margin to the highest safe experimental dose (margin of exposure) was 93. EFSA assesses safety only, not efficacy – within that scope, the conclusion is clear.
- Short-term tolerability has been tested across several studies. The meta-analysis by Yang 2026 pools 15 randomized trials with 250 to 2000 mg per day over 14 days to 24 weeks; liver values remained unremarkable. The period covered ranges from two weeks to just under six months.
- There is one isolated functional finding. In Morifuji 2024, the 4-meter walk time was shorter and the PSQI total sleep score better – both secondary findings from a study whose primary endpoint, a stepping test, was missed. The meta-analysis by Prokopidis 2025 did not confirm this (gait speed MD −0.01; 95% CI −0.08 to 0.06; I²=0%). The finding is therefore a hypothesis, nothing more – and nothing less.
What the studies show
Primary endpoint failed, lab value rose
In a double-blind study (Morifuji 2024), 60 older adults received 250 mg of NMN per day or placebo for twelve weeks. The primary endpoint, a stepping test of leg function, was not met: no difference after either four or twelve weeks. What rose were the secondary lab values – NAD+ in the blood and the breakdown products 2PY and 4PY. In addition, a 4-meter walk time and a sleep questionnaire score were better – secondary findings from a negative study.
Meta-analysis on muscle function: no effect
A meta-analysis of randomized trials in people aged 60.9 to 83 (Prokopidis 2025) found no effect on gait speed: mean difference −0.01 (95 percent confidence interval −0.08 to 0.06; p=0.79) with I-squared equal to 0 percent, meaning the studies did not contradict each other. Skeletal muscle index (−0.42; −0.99 to 0.14; p=0.14) and grip strength also remained unchanged. The paper's conclusion: the evidence does not support the use of NMN and nicotinamide riboside for muscle loss.
Meta-analysis on metabolism: no effect
A meta-analysis of 15 randomized trials (Yang 2026) with 250 to 2000 mg per day over 14 days to 24 weeks found no effects on body weight, BMI, fasting glucose, HbA1c, blood lipids or systolic blood pressure.
Safety signal for the breakdown product 4PY
The niacin end metabolite 4PY, which rises with NMN, was associated with major cardiovascular events over three years in an observational study (Ferrell 2024): adjusted hazard ratio 1.89 (95 percent confidence interval 1.26 to 2.84) and 1.99 (1.26 to 3.14), respectively. A hazard ratio above 1 means more frequent occurrence in the group with higher levels. These are observational data without proof of cause and effect. The finding does not demonstrate harm, but it concerns exactly the metabolic pathway that taking NMN ramps up.
Where the data stop
- A higher NAD level is not proof of benefit. The lab value rises, while the main question of the same study failed. Whether the increase does anything at all therefore remains open.
- No effect on muscle function and metabolism. Two meta-analyses found no effect on gait speed, grip strength and muscle mass, nor on weight, blood sugar, blood lipids or blood pressure.
- The EFSA approval does not demonstrate an effect. This is the most common confusion in marketing – the authority assessed safety only.
Status, approval and legal situation
In 2026, the EFSA Panel on Nutrition and Food Allergens classified beta-NMN as a novel food as safe for adults up to 300 mg per day, excluding pregnant and breastfeeding women; the safety margin to the highest safe experimental dose was 93.
What matters is what this assessment is not: here EFSA examines safety only, not efficacy. A novel food classification does not imply any health benefit. Advertising claims that mix the two turn the facts upside down.
Safety
Short-term tolerability is considered unremarkable: liver values without abnormalities, and EFSA saw no safety concerns for adults up to 300 mg per day. These data cover weeks to months; there is nothing on intake over years.
The signal for the breakdown product 4PY remains open: observational data, not proof of harm, but relevant because taking NMN amplifies exactly this metabolic pathway.
BK-Score Hype far ahead of evidence
| Human evidence | 3 | |
|---|---|---|
| Mechanism | 6 | |
| Safety data | 5 | |
| Hype gap | 2 | |
| Track record of use | 5 |
In humans there are small studies with surrogate markers and no endpoint data; the NAD pathway is plausible, but the increase in tissue is poorly supported. Safety data are short-term only – and hardly any longevity product is more overhyped.
The score rates the state of knowledge, not the substance. “Safety data 9” means well studied – not harmless. “Track record of use 9” means used long and widely – that is not proof of efficacy.
Subjective assessment by Biohacking Kompakt based on published scoring rules – not a scientific rating and not a medical recommendation. Rules and all ratings (German)
Frequently asked questions about NMN
Does NMN really work?
A clinical benefit has not been shown. NAD levels in the blood rise measurably, but that is a lab value, not an outcome. In the study that showed this rise, the primary endpoint failed. Two meta-analyses on muscle function and metabolism found no effects, and studies with hard endpoints are missing entirely.
What does the rise in NAD levels mean?
It means that the substance reaches the body, nothing more. A lab value that is only meant to reflect a course is called a surrogate marker. Whether symptoms, performance or disease rates improve along with the value is a separate question. So far, that very question has remained unanswered or come out negative in every trial.
Does NMN improve muscle strength or walking ability?
No. A meta-analysis of randomized trials in older adults found a mean difference of minus 0.01 for gait speed, with a confidence interval that includes zero. Skeletal muscle index and grip strength were also unchanged. The authors conclude that the evidence does not support its use for muscle loss.
Is NMN approved in the EU?
In 2026, EFSA assessed beta-NMN as a novel food as safe for adults up to 300 mg per day, excluding pregnant and breastfeeding women. This assessment concerns safety only. Efficacy was explicitly not tested and not confirmed, even though the approval is often presented that way.
What are the side effects of NMN?
In the short term, tolerability is considered unremarkable; liver values also showed no abnormalities in the analysis of 15 studies. An open issue is a signal for the breakdown product 4PY, which was associated with major cardiovascular events over three years in observational data. This does not prove harm, but it concerns the metabolic pathway that taking NMN amplifies.
Are there long-term data on NMN?
No. The studies analyzed ran from 14 days to 24 weeks. There is not a single randomized trial on mortality, heart attack, bone fractures or dementia. The largest registered studies, with 200 and 138 participants, have not yet been completed. Statements about years or decades of use currently have no data behind them.
The podcast episode (in German)
Episode 31
AI podcast: NAD+ & NMN – the longevity star, fact-checked
The podcast by Paul Höser (episode 31). AI-generated German episode (Paul & Paula) with expert research. Information only – not medical advice, no dosage or usage recommendation.
Related
- Works together withResveratrol
- Same categoryNicotinamide riboside (NR)
- Same categoryUrolithin A
- Same categoryCa-AKG (calcium alpha-ketoglutarate)
- Also under anti-aging and energyShilajit
- Also under anti-aging and energyPQQ
Sources
- Morifuji 2024, GeroScience – RCT, primary endpoint missed (PMID 38789831)
- Prokopidis 2025, J Cachexia Sarcopenia Muscle – meta-analysis of muscle function (PMID 40275690)
- Yang 2026, Nutrients – meta-analysis of metabolic parameters (PMID 42514320)
- Ferrell 2024, Nature Medicine – safety signal for the metabolite 4PY (PMID 38374343)
- EFSA NDA Panel 2026 – novel food assessment of beta-NMN, safety only (PMID 42125559)
Open in the database – with search, filters and comparison (German app)
Information only, not medical advice and not a usage or dosage recommendation. Prescription drugs and unapproved substances belong in the hands of a doctor. Last updated: 2026-09-13.